Condition: Cholangiocarcinoma · Sponsor: Australasian Gastro-Intestinal Trials Group
The aim of this study is to investigate whether the combination of durvalumab and olaparib in the maintenance setting after initial chemotherapy and durvalumab will benefit patients with locally advanced or metastatic cholangiocarcinoma.
This description comes directly from the study's public registry record.
Clinical Project Manager · 03 9496 3088 · bil.ppp@onjcri.org.au
Sandra Bahamad · +61 7208 2714 · Sandra@gicancer.org.au
Always discuss trial participation with your own doctor first.
| Chris O'Brien Lifehouse | Camperdown, New South Wales, Australia | Recruiting |
| Monash Medical Centre | Clayton, New South Wales, Australia | Recruiting |
| Royal North Shore Hospital | St Leonards, New South Wales, Australia | Recruiting |
| Westmead Hospital | Westmead, New South Wales, Australia | Recruiting |
| Wollongong and Shoalhaven District Memorial Hospital | Wollongong, New South Wales, Australia | Not Yet Recruiting |
| Princess Alexandra Hospital | Woolloongabba, Queensland, Australia | Recruiting |
| Flinders Medical Centre | Bedford Park, South Australia, Australia | Recruiting |
| Austin Health | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06441747